1. Introduction {#sec1}
===============

Ciprofloxacin (CIP), chemically 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid, belongs to the class of the fluoroquinolone antibiotics \[[@B1]\]. It is used to treat bacterial infections such as gastrointestinal, Intra-abdominal, skin, respiratory tract, urinary tract, and bone and joint infections, among others \[[@B2]\]. Doxycycline (DOX), chemically (4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide, is an antibiotic which belongs to the group of tetracyclines \[[@B1]\]. It is used to treat pelvic inflammatory disease, chronic prostatitis, sinusitis, acne, and rickettsial infections in addition to the general indications for all members of the tetracycline antibiotics group \[[@B2]\].

Both ciprofloxacin and doxycycline hyclate are official in the British and United States Pharmacopoeia, and their official method of assay is high-performance liquid chromatography (HPLC) \[[@B1], [@B3]\]. Several analytical methods such as spectrophotometry \[[@B4], [@B5]\], fluorimetry \[[@B6]\], ultra-performance liquid chromatographic \[[@B7]\], HPLC \[[@B8]\], high-performance thin-layer chromatography \[[@B9]\], high-performance capillary electrophoresis \[[@B10]\], and capillary electrophoresis \[[@B11]\] have been reported for the determination of ciprofloxacin while spectrophotometry \[[@B12], [@B13]\] and HPLC \[[@B14], [@B15]\] are for the determination of doxycycline hyclate alone or in combination with other medicines.

In recent years, the application of chemometrics, particularly multivariate calibration methods, is playing a crucial role in the multicomponent analysis of pharmaceutical mixtures \[[@B16]\]. Multivariate calibration methods such as PCR and PLS applied to spectral data are being increasingly used for instrumental methods without separation techniques \[[@B17], [@B18]\]. Multivariate calibration of PCR and PLS have been applied for simultaneous UV-Vis spectrophotometric determination of ciprofloxacin and ornidazole \[[@B19]\], ciprofloxacin and tinidazole \[[@B20]\], ambroxol and doxycycline \[[@B21]\], and *β*-lactam antibiotic binary mixtures \[[@B22]\] in pharmaceutical formulations.

The purpose of this study was to introduce alternative analytical procedures based on the chemometric-assisted spectrophotometric methods for the simultaneous determination of ciprofloxacin and doxycycline hyclate in laboratory-prepared synthetic and pharmaceutical mixtures. Using an apparatus at a time for the simultaneous determination of both drugs using water as a solvent is a great benefit for developing nations because of the efficient use of the instrument and cheap solvent. Therefore, these analytical methods might be helpful specifically in developing countries where resource is limited.

2. Experimental {#sec2}
===============

2.1. Apparatus and Software {#sec2.1}
---------------------------

Spectrophotometric measurements were performed on a double-beam UV-VIS spectrometer (PG Instruments, Lutterworth, England), equipped with 1 cm matched quartz cells, connected to a computer loaded with UV-Win PC software. All absorption spectra were saved and subsequently exported UV-Win software to Microsoft Excel program for statistical manipulation. Minitab 7.1 version software was employed to determine concentrations of combinations for calibration and validation sets while Unscrambler® X 10.5 version was used for PCR and PLS model development and data analysis.

2.2. Reagents and Samples {#sec2.2}
-------------------------

Pharmaceutical grade ciprofloxacin and doxycycline were obtained from Addis Pharmaceutical Factory (Adigrat, Ethiopia). Distilled water was used throughout the work. Commercial samples, ciprofloxacin tablets labeled to contain 500 mg (Serviflox, Sandoz and Zindolin, Remedica) and doxycycline hyclate labeled to contain 100 mg capsules (Doxicad, Cadila), and tablets (Remycin, Remedica), were purchased from the local pharmacies in Mekelle, Ethiopia.

2.3. One-Component Calibration {#sec2.3}
------------------------------

This was examined in the concentration range of 1--10 *μ*g/mL for ciprofloxacin and 5--25 *μ*g/mL for doxycycline hyclate. Absorbance values were recorded at *λ*~max~ of each drug (272 nm for CIP and 275 nm for DOX) against distilled water as blank. Linear dynamic range for each drug was studied by least square linear regression of concentration and the corresponding absorbance.

2.4. Preparation of Stock and Working Standard Solutions {#sec2.4}
--------------------------------------------------------

Accurately weighed and transferred (10 mg) either of the standard drugs into 100 mL volumetric flask was dissolved in about 80 mL of distilled water and diluted to volume with the same solution. Suitable aliquots of the stock solutions were diluted with the solvent to obtain the appropriate working standard solutions according to the linear calibration range for each drug.

2.5. Construction of Calibration and Validation Sets {#sec2.5}
----------------------------------------------------

The calibration and validation mixtures were prepared by combining working standard solutions of CIP and DOX in different ratios in their concentration linearity ranges. The concentrations of mixtures were determined by general factorial design (2 factors at 5 level of each factor) for calibration set and (2 factors at 3 level of each factor) for validation set. A total set of 25 and 9 calibration ([Table 1](#tab1){ref-type="table"}) and validation ([Table 2](#tab2){ref-type="table"}) mixtures were independently prepared, respectively. The absorption spectra of all mixtures were recorded over the range 200--400 nm with 2 nm interval.

2.6. Analysis of the Marketed Formulations {#sec2.6}
------------------------------------------

Twenty tablets or capsules were accurately weighed and finely powdered. Tablet or capsule powder equivalent to ciprofloxacin (100 mg) and doxycycline hyclate (150 mg) were accurately weighed and transferred into 100 mL volumetric flask, and 50 mL of distilled water was added. The solution was well shaken and ultrasonicated for 15 min. Then, the solution was filtrated in a 100 mL volumetric flask through a Whatman filter paper \# 42 filter paper. The residue was washed three times with 10 mL water, and the volume was completed to 100 mL with water. Suitable aliquots of the stock solutions were mixed and diluted with the solvent to obtain the appropriate working sample solution for UV measurements at the specified range.

Synthetic mixture was used for the combination of working standard solutions while pharmaceutical mixture referred to the combination of sample solutions throughout this work.

2.7. Accuracy Study {#sec2.7}
-------------------

The accuracy of the method was performed at three levels 80, 100, and 120% of the working concentration of sample. Calculated amounts of standard solution of CIP and DOX were spiked into sample solution, and the resulting solutions were scanned in the range of 200--400 nm. The accuracy of the method was evaluated as the percent recovery of the added amounts of the standard to the previously analyzed sample. The developed method was validated according to the International Conference on Harmonization (ICH) guidelines.

3. Results and Discussion {#sec3}
=========================

3.1. Multivariate Calibration Analysis {#sec3.1}
--------------------------------------

The UV absorption spectra of ciprofloxacin, doxycycline hyclate, and their mixture are given in [Figure 1](#fig1){ref-type="fig"}. The calibration and prediction sets were designed in 25 and 9 laboratory-made mixtures (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}) as described in [Section 2.5](#sec2.5){ref-type="sec"}. The absorbance spectra which showed a significant overlap were recorded between 200 and 400 nm in the intervals as Δ*λ* = 2 nm at 100 wavelengths. Multivariate calibrations such as PCR and PLS are therefore required for such analysis due to presence of interference.

A number of laboratory synthetic mixtures ([Table 2](#tab2){ref-type="table"}) were subjected to the PCR and PLS analysis to prove the suitability of the calibration model for determination of ciprofloxacin and doxycycline hyclate in the pharmaceutical sample solutions. The model was built with the help of the Unscrambler software. The findings were satisfactory as the concentrations of each drug predicted by the model are close to the actual concentrations.

The predictive abilities of the models were evaluated by root-mean-square error of cross-validation (RMSECV), root-mean-square error of prediction (RMSEP), and correlation coefficient (*r*^2^) ([Table 2](#tab2){ref-type="table"}). With cross-validation, the same calibration set samples were used for both model estimation and testing. Leave-one-out cross-validation, leaving out one sample at a time, was employed to validate the PCR and PLS models in model development. The models were also validated by prediction of the concentration of analytes in separate validation set which was not used in the model development ([Table 2](#tab2){ref-type="table"}). The RMSEP generated from validation set is the estimated prediction error that accurately reflects all sources of variability in the calibration method. To validate the model, both RMSECV and RMSEP must be as low as possible for a model \[[@B23]\]. Reasonable correlation coefficient was obtained for each drug in the validation set samples by PCR- and PLS-optimized models, demonstrating good predictive abilities of the models.

3.2. Accuracy {#sec3.2}
-------------

The reliability and validity of the proposed method were examined by the standard addition technique at 80%, 100%, and 120% of the test concentration. The mixtures were analyzed, and the percent recoveries ranged from 97.50% to 101.87% ([Table 3](#tab3){ref-type="table"}). These findings confirmed that the excipients in pharmaceutical products do not interfere with the determination of ciprofloxacin and doxycycline hyclate.

Precision of the developed method was examined as intra- and interday precisions. Six determinations of the drug solution were performed for three consecutive days for the evaluation of intermediate precision. The percent relative standard deviations of both precisions were \<2%, revealing the good precision of the method.

3.3. Analysis of Real Samples {#sec3.3}
-----------------------------

The proposed methods were applied for the assay of ciprofloxacin and doxycycline hyclate in laboratory prepared mixtures of their pharmaceutical preparations. The assay results are shown in [Table 4](#tab4){ref-type="table"}. The findings were found to be in a good agreement with the concentration taken for the formulations. This revealed that the matrices and/or excipients did not interfere with the quantifications.

The developed techniques are much easier than HPLC methods stipulated in pharmacopeias \[[@B1], [@B3]\] and other existing analytical methods \[[@B7], [@B8], [@B14], [@B15]\]. The methods employed distilled water as a solvent, and the procedures do not involve any sample pretreatment.

4. Conclusion {#sec4}
=============

The developed UV spectrophotometric methods in combination with PCR and PLS can be used for the simultaneous determination of ciprofloxacin and doxycycline hyclate in laboratory-prepared binary mixtures of their either pure powder forms or pharmaceutical preparations. The proposed techniques do not need any sample pretreatment, and they are rapid, precise, and accurate. Therefore, these methods could be suitable for quality-control laboratories especially in developing nations, where resource is limited.
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###### 

Composition of calibration set.

  Mix. no.   CIP (*μ*g/mL)   DOX (*μ*g/mL)
  ---------- --------------- ---------------
  1          1               15
  2          2               7
  3          4               9
  4          1               7
  5          2               5
  6          4               5
  7          6               5
  8          6               12
  9          8               7
  10         4               15
  11         8               5
  12         4               12
  13         4               7
  14         1               12
  15         8               15
  16         6               15
  17         1               5
  18         8               12
  19         2               9
  20         1               9
  21         2               15
  22         2               12
  23         6               9
  24         8               9
  25         6               7

###### 

Composition of validation set and predicted results obtained in synthetic mixtures by PCR and PLS methods.

  CIP         DOX     PCR     PLS                                               
  ----------- ------- ------- -------- ------- -------- ------ -------- ------- --------
  5           13      4.99    99.72    12.96   99.69    4.99   99.73    12.96   99.66
  7           10      7.04    100.60   10.00   100.00   7.04   100.61   10.01   100.05
  5           7       5.09    101.75   7.00    100.00   5.09   101.76   7.00    100.00
  7           7       7.18    102.60   7.09    101.29   7.18   102.61   7.09    101.30
  7           13      7.03    100.50   13.23   101.77   7.04   100.52   13.23   101.79
  5           10      4.95    98.95    9.90    99.00    4.95   98.96    9.90    99.00
  3           7       2.72    90.52    6.68    95.43    2.72   90.55    6.68    95.40
  3           13      2.88    95.98    12.70   97.69    2.88   96.00    12.70   97.66
  3           10      2.79    92.88    9.65    96.50    2.79   92.89    9.65    96.49
  *R* ^2^     0.998   0.994   0.998    0.994                                    
  Intercept   0.376   0.210   0.379    0.210                                    
  Slope       0.932   0.988   0.931    0.988                                    
  RMSECV      0.278   0.794   0.283    0.824                                    
  RMSEP       0.142   0.219   0.143    0.208                                    

*R* ^2^, correlation coefficient; RMSECV, root-mean-square error of cross-validation; RMSEP, root-mean-square error of prediction.

###### 

Accuracy data of CIP and DOX by PCR and PLS models (*n*=3).

  Mix.          Component    Level (%)   Amount taken (*μ*g/mL)   PCR     PLS                                
  ------------- ------------ ----------- ------------------------ ------- -------- -------- ------- -------- -------
  Mix. 1        CIP tablet   80          3.2                      3.12    97.50    0.524    3.13    97.81    0.662
  100           4            3.91        97.75                    0.869   3.90     97.50    0.794            
  120           4.8          4.83        100.63                   0.979   4.82     100.42   1.021            
  DOX capsule   80           8           17.71                    98.39   0.790    17.71    98.39   0.783    
  100           10           20.23       101.15                   0.941   20.24    101.20   0.933            
  120           12           21.73       98.77                    0.834   21.74    98.82    0.829            
                                                                                                             
  Mix. 2        CIP tablet   80          3.2                      3.26    101.87   1.261    3.24    101.25   1.112
  100           4            3.93        98.25                    0.634   3.92     98.00    0.751            
  120           4.8          4.79        99.79                    0.740   4.78     99.58    0.641            
  DOX tablet    80           8           17.82                    99.00   1.111    17.83    99.06   1.101    
  100           10           20.19       100.95                   0.799   20.2     101.00   0.791            
  120           12           21.77       98.95                    0.372   21.79    99.05    0.368            

###### 

Assay results of CIP and DOX in laboratory-prepared commercial mixtures by developed PCR and PLS methods (*n*=3).

  Mix.      Dosage form   Component   Actual conc. (*μ*g/mL)   PCR            PLS                            
  --------- ------------- ----------- ------------------------ -------------- --------------- -------------- -------
  Mix. 1    Tablet        CIP         8                        7.94 ± 0.064   99.19           7.94 ± 0.065   99.25
  Capsule   DOX           12          12.13 ± 0.548            101.08         12.13 ± 0.560   101.08         
                                                                                                             
  Mix 2     Tablet        CIP         8                        7.90 ± 0.039   98.75           7.91 ± 0.041   98.81
  Tablet    DOX           12          11.74 ± 0.974            97.79          11.74 ± 0.041   97.79          
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